Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese Surveillance Committee from 2015 to 2016: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus

Hiroshi Hayami; Satoshi Takahashi; Kiyohito Ishikawa; Mitsuru Yasuda; Shingo Yamamoto; Koichiro Wada; Kanao Kobayashi; Ryoichi Hamasuna; Shinichi Minamitani; Tetsuya Matsumoto; Hiroshi Kiyota; Kazuhiro Tateda; Junko Sato; Hideaki Hanaki; Naoya Masumori; Hiroyuki Nishiyama; Jun Miyazaki; Kiyohide Fujimoto; Kazushi Tanaka; Shinya Uehara; Akio Matsubara; Kenji Ito; Kenji Hayashi; Yuichiro Kurimura; Shin Ito; Toshimi Takeuchi; Harunori Narita; Masanobu Izumitani; Hirofumi Nishimura; Motoshi Kawahara; Makoto Hara; Takahide Hosobe; Kenji Takashima; Hirofumi Chokyu; Masaru Matsumura; Hideari Ihara; Satoshi Uno; Koichi Monden; Toru Sumii; Shuichi Kawai; Satoru Kariya; Takashi Sato; Masaru Yoshioka; Hitoshi Kadena; Shinji Matsushita; Shohei Nishi; Yukinari Hosokawa; Takeshi Shirane; Mutsumasa Yoh; Syuji Watanabe; Shinichi Makinose; Tetsuji Uemura; Hirokazu Goto

doi:10.1016/j.jiac.2019.02.021

Second nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by Japanese Surveillance Committee from 2015 to 2016: antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus

J Infect Chemother. 2019 Jun;25(6):413-422. doi: 10.1016/j.jiac.2019.02.021. Epub 2019 Mar 21.

Authors

Hiroshi Hayami¹, Satoshi Takahashi², Kiyohito Ishikawa³, Mitsuru Yasuda⁴, Shingo Yamamoto⁵, Koichiro Wada⁶, Kanao Kobayashi⁷, Ryoichi Hamasuna⁸, Shinichi Minamitani⁹, Tetsuya Matsumoto¹⁰, Hiroshi Kiyota¹¹, Kazuhiro Tateda¹⁰, Junko Sato¹⁰, Hideaki Hanaki¹², Naoya Masumori¹³, Hiroyuki Nishiyama¹⁴, Jun Miyazaki¹⁴, Kiyohide Fujimoto¹⁵, Kazushi Tanaka¹⁶, Shinya Uehara¹⁷, Akio Matsubara¹⁸, Kenji Ito¹⁹, Kenji Hayashi²⁰, Yuichiro Kurimura²⁰, Shin Ito²¹, Toshimi Takeuchi²², Harunori Narita²³, Masanobu Izumitani²⁴, Hirofumi Nishimura²⁵, Motoshi Kawahara²⁶, Makoto Hara²⁷, Takahide Hosobe²⁸, Kenji Takashima²⁹, Hirofumi Chokyu³⁰, Masaru Matsumura³¹, Hideari Ihara³², Satoshi Uno³³, Koichi Monden³⁴, Toru Sumii³⁵, Shuichi Kawai³⁶, Satoru Kariya³⁷, Takashi Sato³⁸, Masaru Yoshioka³⁹, Hitoshi Kadena⁴⁰, Shinji Matsushita⁴¹, Shohei Nishi⁴², Yukinari Hosokawa⁴³, Takeshi Shirane⁴⁴, Mutsumasa Yoh⁴⁵, Syuji Watanabe⁴⁶, Shinichi Makinose⁴⁷, Tetsuji Uemura⁴⁸, Hirokazu Goto⁴⁹

Affiliations

¹ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Blood Purification Center, Kagoshima University Hospital, Kagoshima, Japan. Electronic address: bass@m.kufm.kagoshima-u.ac.jp.
² The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
³ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, School of Medicine, Fujita Health University, Toyoake, Japan.
⁴ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Gifu University Hospital, Gifu, Japan.
⁵ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Hyogo College of Medicine, Hyogo, Japan.
⁶ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
⁷ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, Chugoku Rosai Hospital, Hiroshima, Japan.
⁸ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
⁹ The Urogenital Sub-committee and the Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Daiichi Sankyo Co., Ltd, Japan.
¹⁰ The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan.
¹¹ The Surveillance Committee of JSC, JAID and JSCM, Tokyo, Japan; Department of Urology, The Jikei University Katsushika Medical Center, Tokyo, Japan.
¹² Infection Control Research Center, Kitasato University, Tokyo, Japan.
¹³ Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, Japan.
¹⁴ Department of Urology, University of Tsukuba, Ibaraki, Japan.
¹⁵ Department of Urology, Nara Medical University, Nara, Japan.
¹⁶ Division of Urology, Department of Surgery Related Faculty of Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan.
¹⁷ Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
¹⁸ Department of Urology, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
¹⁹ Ito Urology Clinic, Fukuoka, Japan.
²⁰ Tomakomai Urology and Cardiology Clinic, Hokkaido, Japan.
²¹ iClinic, Miyagi, Japan.
²² Takeuchi Urology and Dermatology Clinic, Gifu, Japan.
²³ Narita Clinic, Aichi, Japan.
²⁴ Izumitani Fureai Clinic, Aichi, Japan.
²⁵ Nishimura Urology Clinic, Fukuoka, Japan.
²⁶ Kawahara Urology Clinic, Kagoshima, Japan.
²⁷ Department of Urology, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
²⁸ Hosobe Clinic, Tokyo, Japan.
²⁹ Takashima Urology Clinic, Nara, Japan.
³⁰ Cyokyu Tenma Clinic, Hyogo, Japan.
³¹ Matsumura Urology Clinic, Hyogo, Japan.
³² Ihara Clinic, Hyogo, Japan.
³³ Hirajima Clinic, Okayama, Japan.
³⁴ Araki Urological Clinic, Okayama, Japan.
³⁵ Sumii Clinic, Hiroshima, Japan.
³⁶ Kawai Urology Clinic, Fukuoka, Japan.
³⁷ Ootemachi Clinic, Kagoshima, Japan.
³⁸ Nissin Urological Clinic, Hokkaido, Japan.
³⁹ Yoshioka Urology Clinic, Hyogo, Japan.
⁴⁰ Kadena Urological Clinic, Hiroshima, Japan.
⁴¹ Department of Urology, Kagoshima Prefectural Ohshima Hospital, Kagoshima, Japan.
⁴² Nishi Urology and Dermatology Clinic, Fukuoka, Japan.
⁴³ Department of Urology, Tane General Hospital, Osaka, Japan.
⁴⁴ Shirane Urology Clinic, Hiroshima, Japan.
⁴⁵ Yoh Urology and Dermatology Clinic, Aichi, Japan.
⁴⁶ Department of Urology, Saiseikai Chuwa Hospital, Nara, Japan.
⁴⁷ Makinose Urological Clinic, Kagoshima, Japan.
⁴⁸ Remedy Kitakyushu Nephro Clinic, Fukuoka, Japan.
⁴⁹ Department of Urology, Fuji City Genaral Hospital, Shizuoka, Japan.

PMID: 30905628
DOI: 10.1016/j.jiac.2019.02.021

Abstract

The Japanese Surveillance Committee conducted a second nationwide surveillance of antimicrobial susceptibility patterns of uropathogens responsible for acute uncomplicated cystitis (AUC) in premenopausal patients aged 16-40 years old at 31 hospitals throughout Japan from March 2015 to February 2016. In this study, the susceptibility of causative bacteria (Escherichia coli, Klebsiella pneumoniae, Staphylococcus saprophyticus) for various antimicrobial agents was investigated by isolation and culturing of organisms obtained from urine samples. In total, 324 strains were isolated from 361 patients, including E. coli (n = 220, 67.9%), S. saprophyticus (n = 36, 11.1%), and K. pneumoniae (n = 7, 2.2%). The minimum inhibitory concentrations (MICs) of 20 antibacterial agents for these strains were determined according to the Clinical and Laboratory Standards Institute (CLSI) manual. At least 93% of the E. coli isolates showed susceptibility to fluoroquinolones and cephalosporins, whereas 100% of the S. saprophyticus isolates showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing E. coli strains were 6.4% (13/220) and 4.1% (9/220), respectively. The antimicrobial susceptibility of K. pneumoniae was retained during the surveillance period, while no multidrug-resistant strains were identified. In summary, antimicrobial susceptibility results of our second nationwide surveillance did not differ significantly from those of the first surveillance. Especially the numbers of fluoroquinolone-resistant and ESBL-producing E. coli strains were not increased in premenopausal patients with AUC in Japan.

Keywords: Acute uncomplicated cystitis; Resistance; Surveillance; Susceptibility.

Publication types

Multicenter Study

MeSH terms

Adolescent
Adult
Anti-Bacterial Agents / pharmacology*
Anti-Bacterial Agents / therapeutic use
Cystitis / drug therapy*
Cystitis / epidemiology
Cystitis / microbiology
Drug Resistance, Multiple, Bacterial*
Epidemiological Monitoring
Escherichia coli / drug effects*
Escherichia coli / isolation & purification
Escherichia coli / metabolism
Female
Humans
Japan
Klebsiella pneumoniae / drug effects*
Klebsiella pneumoniae / isolation & purification
Klebsiella pneumoniae / metabolism
Male
Microbial Sensitivity Tests
Middle Aged
Staphylococcus saprophyticus / drug effects*
Staphylococcus saprophyticus / isolation & purification
Staphylococcus saprophyticus / metabolism
Young Adult
beta-Lactamases / metabolism

Substances

Anti-Bacterial Agents
beta-Lactamases